307 related articles for article (PubMed ID: 11451447)
41. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
42. PAC1 receptors mediate pituitary adenylate cyclase-activating polypeptide- and progesterone-facilitated receptivity in female rats.
Apostolakis EM; Riherd DN; O'Malley BW
Mol Endocrinol; 2005 Nov; 19(11):2798-811. PubMed ID: 15976009
[TBL] [Abstract][Full Text] [Related]
43. Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells.
Inagaki N; Yoshida H; Mizuta M; Mizuno N; Fujii Y; Gonoi T; Miyazaki J; Seino S
Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2679-83. PubMed ID: 8146174
[TBL] [Abstract][Full Text] [Related]
44. Domains determining agonist selectivity in chimaeric VIP2 (VPAC2)/PACAP (PAC1) receptors.
Lutz EM; MacKenzie CJ; Johnson M; West K; Morrow JA; Harmar AJ; Mitchell R
Br J Pharmacol; 1999 Oct; 128(4):934-40. PubMed ID: 10556928
[TBL] [Abstract][Full Text] [Related]
45. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
46. Localization of the pituitary adenylate cyclase-activating polypeptide receptor and its mRNA in the rat adrenal medulla.
Shioda S; Shimoda Y; Hori T; Mizushima H; Ajiri T; Funahashi H; Ohtaki K; Ryushi T
Neurosci Lett; 2000 Dec; 295(3):81-4. PubMed ID: 11090979
[TBL] [Abstract][Full Text] [Related]
47. Altered emotional behavior in PACAP-type-I-receptor-deficient mice.
Otto C; Martin M; Wolfer DP; Lipp HP; Maldonado R; Schütz G
Brain Res Mol Brain Res; 2001 Aug; 92(1-2):78-84. PubMed ID: 11483244
[TBL] [Abstract][Full Text] [Related]
48. Pituitary adenylate cyclase-activating polypeptide receptors of types I and II and glucagon-like peptide-I receptors are expressed in the rat medullary carcinoma of the thyroid cell line 6/23.
Vertongen P; Ciccarelli E; Woussen-Colle MC; De Neef P; Robberecht P; Cauvin A
Endocrinology; 1994 Oct; 135(4):1537-42. PubMed ID: 7925114
[TBL] [Abstract][Full Text] [Related]
49. Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation.
Pantaloni C; Brabet P; Bilanges B; Dumuis A; Houssami S; Spengler D; Bockaert J; Journot L
J Biol Chem; 1996 Sep; 271(36):22146-51. PubMed ID: 8703026
[TBL] [Abstract][Full Text] [Related]
50. Expression of pituitary adenylate cyclase activating polypeptide and its type I receptor mRNAs in human placenta.
Koh PO; Won CK; Noh HS; Cho GJ; Choi WS
J Vet Sci; 2005 Mar; 6(1):1-5. PubMed ID: 15785117
[TBL] [Abstract][Full Text] [Related]
51. PACAP promotes neural stem cell proliferation in adult mouse brain.
Mercer A; Rönnholm H; Holmberg J; Lundh H; Heidrich J; Zachrisson O; Ossoinak A; Frisén J; Patrone C
J Neurosci Res; 2004 Apr; 76(2):205-15. PubMed ID: 15048918
[TBL] [Abstract][Full Text] [Related]
52. Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP.
Lutz EM; Ronaldson E; Shaw P; Johnson MS; Holland PJ; Mitchell R
Mol Cell Neurosci; 2006 Feb; 31(2):193-209. PubMed ID: 16226889
[TBL] [Abstract][Full Text] [Related]
53. Expression of PACAP, and PACAP type 1 (PAC1) receptor mRNA during development of the mouse embryo.
Sheward WJ; Lutz EM; Copp AJ; Harmar AJ
Brain Res Dev Brain Res; 1998 Aug; 109(2):245-53. PubMed ID: 9729410
[TBL] [Abstract][Full Text] [Related]
54. Differentiation induces pituitary adenylate cyclase-activating polypeptide receptor expression in PC-12 cells.
Cavallaro S; D'Agata V; Guardabasso V; Travali S; Stivala F; Canonico PL
Mol Pharmacol; 1995 Jul; 48(1):56-62. PubMed ID: 7623775
[TBL] [Abstract][Full Text] [Related]
55. Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain.
Joo KM; Chung YH; Kim MK; Nam RH; Lee BL; Lee KH; Cha CI
J Comp Neurol; 2004 Aug; 476(4):388-413. PubMed ID: 15282712
[TBL] [Abstract][Full Text] [Related]
56. Antagonistic properties are shifted back to agonistic properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 cell membranes.
Vandermeers A; Vandenborre S; Hou X; de Neef P; Robberecht P; Vandermeers-Piret MC; Christophe J
Eur J Biochem; 1992 Sep; 208(3):815-9. PubMed ID: 1327769
[TBL] [Abstract][Full Text] [Related]
57. Expression of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumors.
Robberecht P; Woussen-Colle MC; Vertongen P; De Neef P; Hou X; Salmon I; Brotchi J
Peptides; 1994; 15(4):661-5. PubMed ID: 7937342
[TBL] [Abstract][Full Text] [Related]
58. Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist.
Robberecht P; Gourlet P; De Neef P; Woussen-Colle MC; Vandermeers-Piret MC; Vandermeers A; Christophe J
Eur J Biochem; 1992 Jul; 207(1):239-46. PubMed ID: 1321043
[TBL] [Abstract][Full Text] [Related]
59. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery.
Vaudry D; Falluel-Morel A; Bourgault S; Basille M; Burel D; Wurtz O; Fournier A; Chow BK; Hashimoto H; Galas L; Vaudry H
Pharmacol Rev; 2009 Sep; 61(3):283-357. PubMed ID: 19805477
[TBL] [Abstract][Full Text] [Related]
60. Cytosolic Ca2+ responses to sub-picomolar and nanomolar PACAP in pancreatic beta-cells are mediated by VPAC2 and PAC1 receptors.
Yamada H; Watanabe M; Yada T
Regul Pept; 2004 Dec; 123(1-3):147-53. PubMed ID: 15518905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
